PDCD1 and melanoma: The results from 49 evaluable patients with Stage IIIC-IV, anti-PD-1 refractory melanoma treated with tilsotolimod and ipilimumab in a phase 2 trial (NCT02644967) published in 2020 included an ORR of 22% and median OS of 21 months (Figure 1) [84].